reference/30171309

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30171309

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	6624
issn	1078-0432 1557-3265
issueIdentifier	18
pageRange	6615-6624
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	6615
bibliographicCitation	Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15;11(18):6615–24. doi: 10.1158/1078-0432.ccr-05-0650. PMID: 16166440.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d364474d375c00a5173abc2ddf6434c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8c1de7da4deb440ed2ecc8697edce38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_015c529c5402937bd8dbb3c3e95ce39f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7802b8144690dcab0cd4e91fb76e393 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e39f8fcb6ea98aaf9fcc56cb3c559a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c45f85cd3fc63ae2d5d6796f14859a7a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a772cdbe55a769a2f9df295a030f4bcf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c228d2ca0db914758e611bcc98219610 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88cc0f7b787db0f92bbc6b90d1a3f03a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d361124df9f3658802fe19afde70f65 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9bca2b6f3ba5ce11c145debec8abc863 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_608fbffe7b9601a9f6deaf600fda0fed http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4190883552be9e16fc03bddc09e5f0ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f11ea9c92dc59998ab041e02911acc0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e9acd5d12a5f07c295d018f941d8f94 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b010671c2d90c083d5256b16afb62beb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f06b9c8bff3a48643930c44e16d0a533 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2cc509285e92756f7b134d15a540d979 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e605c269adda7e5090582abbca5a213a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6d00d3aba027043e0cfebb59b17c883
date	2005-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1158/1078-0432.ccr-05-0650 https://pubmed.ncbi.nlm.nih.gov/16166440
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
discusses	http://id.nlm.nih.gov/mesh/M0022142 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0028878 http://id.nlm.nih.gov/mesh/M0024087 http://id.nlm.nih.gov/mesh/M0028384 http://id.nlm.nih.gov/mesh/M0288458 http://id.nlm.nih.gov/mesh/M0473025 http://id.nlm.nih.gov/mesh/M0172205 http://id.nlm.nih.gov/mesh/M0016238 http://id.nlm.nih.gov/mesh/M0009493 http://id.nlm.nih.gov/mesh/M0026536
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D013449Q000627 http://id.nlm.nih.gov/mesh/D019337Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D009190Q000235 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D009190Q000097 http://id.nlm.nih.gov/mesh/D009190Q000188 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D006023Q000032 http://id.nlm.nih.gov/mesh/D015703Q000032 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D009364 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D042783Q000737 http://id.nlm.nih.gov/mesh/D000071916 http://id.nlm.nih.gov/mesh/D014839Q000139 http://id.nlm.nih.gov/mesh/D009360Q000737 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D019408Q000032 http://id.nlm.nih.gov/mesh/D019008 http://id.nlm.nih.gov/mesh/D019337Q000235 http://id.nlm.nih.gov/mesh/D003248Q000139 http://id.nlm.nih.gov/mesh/D009325Q000139 http://id.nlm.nih.gov/mesh/D003967Q000139 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D019006Q000032 http://id.nlm.nih.gov/mesh/D014404Q000235 http://id.nlm.nih.gov/mesh/D013449Q000009 http://id.nlm.nih.gov/mesh/D008870Q000378 http://id.nlm.nih.gov/mesh/D017493Q000032 http://id.nlm.nih.gov/mesh/D019337Q000097 http://id.nlm.nih.gov/mesh/D007938Q000188 http://id.nlm.nih.gov/mesh/D007938Q000235 http://id.nlm.nih.gov/mesh/D007938Q000097 http://id.nlm.nih.gov/mesh/D010455Q000032 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D000208 http://id.nlm.nih.gov/mesh/D051929 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7333 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID602 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8560 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6288 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5950 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10364 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460797 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460795 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3035714 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8306 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10820

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID203068

Total number of triples: 107.